CL2014000291A1 - Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer. - Google Patents
Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer.Info
- Publication number
- CL2014000291A1 CL2014000291A1 CL2014000291A CL2014000291A CL2014000291A1 CL 2014000291 A1 CL2014000291 A1 CL 2014000291A1 CL 2014000291 A CL2014000291 A CL 2014000291A CL 2014000291 A CL2014000291 A CL 2014000291A CL 2014000291 A1 CL2014000291 A1 CL 2014000291A1
- Authority
- CL
- Chile
- Prior art keywords
- prophylaxis
- vaccine
- cancer
- treatment
- nucleic acid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161521280P | 2011-08-08 | 2011-08-08 | |
RU2012108927 | 2012-03-11 | ||
PCT/US2012/050024 WO2013022991A2 (en) | 2011-08-08 | 2012-08-08 | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014000291A1 true CL2014000291A1 (es) | 2014-08-08 |
Family
ID=47669212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014000291A CL2014000291A1 (es) | 2011-08-08 | 2014-02-05 | Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer. |
Country Status (15)
Country | Link |
---|---|
US (3) | US9717781B2 (es) |
EP (1) | EP2750694B8 (es) |
JP (1) | JP6193231B2 (es) |
KR (1) | KR102001582B1 (es) |
CN (1) | CN103889440A (es) |
AU (1) | AU2012294454B2 (es) |
BR (1) | BR112014002817A2 (es) |
CA (1) | CA2844283A1 (es) |
CL (1) | CL2014000291A1 (es) |
EA (1) | EA026228B1 (es) |
HK (1) | HK1200086A1 (es) |
IL (1) | IL230770A0 (es) |
MX (1) | MX353299B (es) |
SG (1) | SG2014008411A (es) |
WO (1) | WO2013022991A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441810B2 (en) * | 2007-04-08 | 2019-10-15 | Immunolight, Llc | X-ray psoralen activated cancer therapy (X-PACT) |
AU2012294454B2 (en) * | 2011-08-08 | 2017-02-02 | Curelab Oncology, Inc. | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
US20130345143A1 (en) * | 2012-01-31 | 2013-12-26 | Rutgers, The State University Of New Jersey | MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN |
EP2978774A1 (en) * | 2013-03-29 | 2016-02-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceuticals compositions for treating breast cancers |
CN106061501A (zh) * | 2013-12-29 | 2016-10-26 | Cl昂科莱吉有限公司 | 用于治疗和预防炎症相关疾病的涉及p62/sqstm1的方法和组合物 |
CN105079780B (zh) * | 2014-05-04 | 2020-07-14 | 中国医学科学院药物研究所 | 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用 |
WO2016082192A1 (zh) * | 2014-11-28 | 2016-06-02 | 中国医学科学院药物研究所 | 与trb3蛋白特异性结合的多肽,其筛选方法、鉴定和用途 |
CN106063928B (zh) * | 2015-04-23 | 2020-07-14 | 中国医学科学院药物研究所 | 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用 |
WO2016207730A1 (en) * | 2015-06-22 | 2016-12-29 | The University Of Oslo | Targeting of vaccine antigen to an intracellular compartment |
JP6965252B2 (ja) | 2015-10-19 | 2021-11-10 | イミュノライト・エルエルシー | X線ソラレン活性化がん治療(x−pact) |
US11725035B2 (en) | 2016-08-09 | 2023-08-15 | Stipe Therapeutics Aps | Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity |
CN106153922B (zh) * | 2016-09-14 | 2018-03-06 | 深圳大学 | 一种结肠癌预后预测标志物及其检测方法 |
CA3090659A1 (en) * | 2018-02-06 | 2019-08-15 | Stipe Therapeutics Aps | Modulation of p62 and sting activity |
WO2020028923A2 (en) * | 2018-08-02 | 2020-02-06 | Curelab Oncology, Inc. | Compositions and methods relating to p62 for the treatment and prophylaxis of age-related macular degeneration |
CN116710475A (zh) * | 2020-12-15 | 2023-09-05 | 国家科学研究中心 | Sqstm1及其在癌症疗法中的用途 |
CN114106207B (zh) * | 2022-01-24 | 2022-04-26 | 诺未科技(北京)有限公司 | Ccl5的用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
EP0347425B1 (en) | 1987-03-02 | 1995-12-27 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
JPH05504067A (ja) | 1990-02-26 | 1993-07-01 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | 大腸菌及びマイコバクテリアのためのシャトルプラスミド |
GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5610276A (en) * | 1991-05-17 | 1997-03-11 | Chiron Corporation | Polypeptides and antibodies derived from GAP associated protein, p62 |
AU2185592A (en) | 1991-06-06 | 1993-01-08 | Med Immune, Inc. | Induction of ctl responses to foreign antigens expressed in mycobacteria |
FR2734826B1 (fr) * | 1995-06-01 | 1997-07-04 | Rhone Poulenc Rorer Sa | Deltap62, ses variants, sequences nucleiques et leurs utilisations |
US5962224A (en) * | 1995-12-19 | 1999-10-05 | Dana-Farber Cancer Institute | Isolated DNA encoding p62 polypeptides and uses therefor |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
EP1109582A4 (en) | 1998-08-18 | 2004-11-03 | Res Dev Foundation | METHOD FOR STRENGTHENING AND RESTRICTING GENE EXPRESSION |
AU2001272932A1 (en) | 2000-06-02 | 2001-12-17 | Entremed, Inc | Angiostatin and endostatin binding proteins and methods of use |
US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
WO2003095607A2 (en) * | 2002-05-14 | 2003-11-20 | Jaekyoon Shin | Role of p62 in aging-related disease |
JP2008502588A (ja) * | 2003-12-12 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−5調節物質及びその使用 |
US8444973B2 (en) * | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
EP2221063A1 (en) * | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
EP2456790A1 (en) * | 2009-07-20 | 2012-05-30 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
WO2011083637A1 (ja) * | 2010-01-07 | 2011-07-14 | 財団法人東京都医学総合研究所 | 肝疾患治療薬 |
AU2012294454B2 (en) * | 2011-08-08 | 2017-02-02 | Curelab Oncology, Inc. | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
-
2012
- 2012-08-08 AU AU2012294454A patent/AU2012294454B2/en active Active
- 2012-08-08 MX MX2014001418A patent/MX353299B/es active IP Right Grant
- 2012-08-08 BR BR112014002817A patent/BR112014002817A2/pt not_active Application Discontinuation
- 2012-08-08 CN CN201280048472.3A patent/CN103889440A/zh active Pending
- 2012-08-08 EP EP12821946.6A patent/EP2750694B8/en active Active
- 2012-08-08 KR KR1020147005822A patent/KR102001582B1/ko active IP Right Grant
- 2012-08-08 JP JP2014525126A patent/JP6193231B2/ja active Active
- 2012-08-08 EA EA201490423A patent/EA026228B1/ru active IP Right Revival
- 2012-08-08 US US14/236,829 patent/US9717781B2/en active Active
- 2012-08-08 SG SG2014008411A patent/SG2014008411A/en unknown
- 2012-08-08 CA CA2844283A patent/CA2844283A1/en active Pending
- 2012-08-08 WO PCT/US2012/050024 patent/WO2013022991A2/en active Application Filing
-
2014
- 2014-02-02 IL IL230770A patent/IL230770A0/en unknown
- 2014-02-05 CL CL2014000291A patent/CL2014000291A1/es unknown
-
2015
- 2015-01-06 HK HK15100087.7A patent/HK1200086A1/xx unknown
-
2016
- 2016-11-01 US US15/340,118 patent/US10716837B2/en active Active
-
2020
- 2020-07-17 US US16/931,655 patent/US20200338176A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013022991A3 (en) | 2013-04-18 |
US20170043002A1 (en) | 2017-02-16 |
MX2014001418A (es) | 2014-09-15 |
WO2013022991A2 (en) | 2013-02-14 |
JP2014527053A (ja) | 2014-10-09 |
AU2012294454A1 (en) | 2014-02-13 |
KR20140083976A (ko) | 2014-07-04 |
EP2750694B8 (en) | 2018-11-14 |
MX353299B (es) | 2018-01-08 |
SG2014008411A (en) | 2014-03-28 |
HK1200086A1 (en) | 2015-07-31 |
US10716837B2 (en) | 2020-07-21 |
CN103889440A (zh) | 2014-06-25 |
KR102001582B1 (ko) | 2019-07-18 |
JP6193231B2 (ja) | 2017-09-06 |
AU2012294454B2 (en) | 2017-02-02 |
EA201490423A1 (ru) | 2014-07-30 |
BR112014002817A2 (pt) | 2021-09-08 |
EP2750694A2 (en) | 2014-07-09 |
EA026228B1 (ru) | 2017-03-31 |
IL230770A0 (en) | 2014-03-31 |
EP2750694A4 (en) | 2015-04-15 |
US9717781B2 (en) | 2017-08-01 |
EP2750694B1 (en) | 2018-09-19 |
US20200338176A1 (en) | 2020-10-29 |
US20140161824A1 (en) | 2014-06-12 |
CA2844283A1 (en) | 2013-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014000291A1 (es) | Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer. | |
CL2014000630A1 (es) | Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc. | |
CL2014001956A1 (es) | Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas. | |
CL2015000482A1 (es) | Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b | |
CL2016002235A1 (es) | Composiciones útiles en el tratamiento de deficiencia de ornitina-transcarbamilasa (otc) | |
CL2014000311A1 (es) | Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio. | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
CO7071129A2 (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
CL2015000420A1 (es) | Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3. | |
ES2860688T8 (es) | Pirrolopirimidinas para uso en la infección por el virus de la gripe | |
DK3134105T3 (da) | Peptidanaloger med én eller flere forgrenede aminosyreprober | |
ES2965637T3 (es) | Procedimiento para la producción de ácido orto-aminobenzoico y/o anilina mediante levadura recombinante | |
IL251571B (en) | Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran | |
SG11201701384XA (en) | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg | |
CL2013002908A1 (es) | Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia . | |
CL2013003285A1 (es) | Cepas de salmonella gallinarum modificadas avirulentas; composicion farmaceutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonella gallinarum. | |
EP3223809A4 (en) | Amino acid compositions for the treatment of symptoms of disease | |
BR112014021927A2 (pt) | composição farmacêutica antirretroviral, processo para preparar uma composição farmacêutica antirretroviral, método para o tratamento ou profilaxia de doenças causadas por retrovírus, e, uso de lamivudina, festinavir e nevirapina | |
CL2014000394A1 (es) | Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos. | |
HK1246694A1 (zh) | α胸腺肽用於膿毒症治療的用途 | |
ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido |